FGFR1 and acute myeloid leukemia: Our analysis of the publicly available databases indicated that mutation JAK2 V617F was found in 6% of blasts from AML patients, and that expressions of FGFR1 and JAK3 were significantly higher in AML patients than in healthy people (Figure S1 and Figure 1).